An Open-Label, Randomized Study of a 9-Valent Human Papillomavirus Vaccine Given Concomitantly with Diphtheria, Tetanus, Pertussis and Poliomyelitis Vaccines to Healthy Adolescents 11-15 Years of Age

Pediatric Infectious Disease Journal

Volumn 34, Issue 6, 2015, Pages 627-634

  Kosalaraksa, Pope ^a   Mehlsen, Jesper ^b   Vesikari, Timo ^c   Forstén, Aino ^c   Helm, Klaus ^d   Van Damme, Pierre ^e   Joura, Elmar A ^f   Ciprero, Karen ^g   Maansson, Roger ^h   Luxembourg, Alain ^h   Sobanjo Ter Meulen, Ajoke ^h  

^a KHON KAEN UNIVERSITY   (Thailand)

^b FREDERIKSBERG HOSPITAL   (Denmark)

^c TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^d Paulinenstr 71 A   (Germany)

^e UNIVERSITY OF ANTWERP   (Belgium)

^f UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

^g Department of Clinical Research Vaccines ^*  (Austria)

^h MERCK RESEARCH LABORATORIES   (United States)

Author keywords

concomitant; GARDASIL; HPV vaccine; REPEVAX

Indexed keywords

ANTIGEN; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS VACCINE; NEUTRALIZING ANTIBODY; WART VIRUS VACCINE; BACTERIUM ANTIBODY; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DTPP VACCINE; POLIOMYELITIS VACCINE; VACCINE; VIRUS ANTIBODY;

ADOLESCENCE; ADOLESCENT; ARTICLE; CHILD; CONTROLLED STUDY; DIPHTHERIA; DRUG SAFETY; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE REACTION; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERTUSSIS; POLIOMYELITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SEROLOGY; TETANUS; VACCINATION; ADVERSE EFFECTS; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; IMMUNOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; NORMAL HUMAN; PAPILLOMAVIRUS INFECTIONS; PATHOLOGY; PROCEDURES;

ADOLESCENT; ANTIBODIES, BACTERIAL; ANTIBODIES, VIRAL; CHILD; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HEALTHY VOLUNTEERS; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; POLIOVIRUS VACCINE, INACTIVATED; VACCINATION; VACCINES, COMBINED;

EID: 84937709058     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000694     Document Type: Article

References (37)

1. Forman D, de Martel C, Lacey CJ, Global burden of human papillomavirus and related diseases. Vaccine 2012 30 Suppl 5 F12 F23
2. Garland SM, Hernandez-Avila M, Wheeler CM, Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007 356 1928 1943
3. FUTURE II Study Group Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007 356 1915 1927
4. Munoz N, Manalastas R, Pitisuttihum P, Safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women between 24 and 45 years of age: a randomized, double-blind trial. Lancet 2009 373 1949 1957
5. Palefsky JM, Giuliano AR, Goldstone S, HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011 365 1576 1585
6. Giuliano AR, Palefsky JM, Goldstone S, Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med 2011 364 401 411
7. Paavonen J, Jenkins D, Bosch FX, HPV PATRICIA study group Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007 369 2161 2170
8. Markowitz LE, Hariri S, Lin C, Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. J Infect Dis 2013 208 385 393
9. Tabrizi SN, Brotherton JM, Kaldor JM, Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis 2012 206 1645 1651
10. Brotherton JM, Fridman M, May CL, Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011 377 2085 2092
11. Powell SE, Hariri S, Steinau M, Impact of human papillomavirus (HPV) vaccination on HPV 16/18-related prevalence in precancerous cervical lesions. Vaccine 2012 31 109 113
12. Gertig DM, Brotherton JM, Budd AC, Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. BMC Med 2013 11 227
13. Ali H, Donovan B, Wand H, Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ 2013 346 f2032
14. Ali H, Guy RJ, Wand H, Decline in in-patient treatments of genital warts among young Australians following the national HPV vaccination program. BMC Infect Dis 2013 13 140
15. Read TR, Hocking JS, Chen MY, The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect 2011 87 544 547
16. Bauer HM, Wright G, Chow J., Evidence of human papillomavirus vaccine effectiveness in reducing genital warts: an analysis of California public family planning administrative claims data, 2007-2010. Am J Public Health 2012 102 833 835
17. Nsouli-Maktabi H, Ludwig SL, Yerubandi UD, Incidence of genital warts among U.S. service members before and after the introduction of the quadrivalent human papillomavirus vaccine. MSMR 2013 20 17 20
18. Leval A, Herweijer E, Arnheim-Dahlström L, Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability. J Infect Dis 2012 206 860 866
19. Baandrup L, Blomberg M, Dehlendorff C, Significant decrease in the incidence of genital warts in young Danish women after implementation of a national human papillomavirus vaccination program. Sex Transm Dis 2013 40 130 135
20. Mikolajczyk RT, Kraut AA, Horn J, Changes in incidence of anogenital warts diagnoses after the introduction of human papillomavirus vaccination in Germany-an ecologic study. Sex Transm Dis 2013 40 28 31
21. Blomberg M, Dehlendorff C, Munk C, Strongly decreased risk of genital warts after vaccination against human papillomavirus: nationwide follow-up of vaccinated and unvaccinated girls in Denmark. Clin Infect Dis 2013 57 929 934
22. Deleré Y, Remschmidt C, Leuschner J, Human Papillomavirus prevalence and probable first effects of vaccination in 20 to 25 year-old women in Germany: a population-based cross-sectional study via home-based self-sampling. BMC Infect Dis 2014 14 87
23. Baldur-Felskov B, Dehlendorff C, Munk C, Early impact of human papillomavirus vaccination on cervical neoplasia-nationwide follow-up of young Danish women. J Natl Cancer Inst 2014 106 djt460
24. Mesher D, Soldan K, Howell-Jones R, Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in England. Vaccine 2013 32 26 32
25. Kavanagh K, Pollock KG, Potts A, Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types. Br J Cancer 2014 110 2804 2811
26. International Agency for Research on Cancer IARC monographs on the evaluation of carcinogenic risks to humans: Vol 100, a review of human carcinogens. Part B: biological agents 2011. Available at: http://monographs.iarc.fr/ENG/Monographs/vol100B/mono100B-1.pdf. Accessed April 20, 2015
27. Serrano B, Alemany L, Tous S, Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agent Cancer 2012 7 38
28. Joura EA, Giuliano AR, Iversen OE, A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 2015 372 711 723
29. Broder KR, Cortese MM, Iskander JK, Advisory Committee on Immunization Practices (ACIP) Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006 55 1 34
30. European Centre for Disease Prevention and Control (ECDC) Guidance-Scientific panel on childhood immunization schedule: diphtheria-tetanus-pertussis (DTP) vaccination (2009). Available at: http://www.ecdc.europa.eu/en/publications/Publications/0911-GUI-Scientific-Panel-on-Childhood-Immunisation-DTP.pdf. Accessed July 25, 2014
31. Markowitz LE, Tsu V, Deeks SL, Human papillomavirus vaccine introduction-the first five years. Vaccine 2012 30 Suppl 5 F139 F148
32. Vesikari T, Van Damme P, Lindblad N, An open-label, randomized, multicenter study of the safety, tolerability, and immunogenicity of quadrivalent HPV (types 6/11/16/18) vaccine given concomitantly with diphtheria, tetanus, pertussis and poliomyelitis vaccine in healthy adolescents 11-17 years of age. Pediatr Infect Dis J 2010 29 314 318
33. Roberts C, Green T, Hess E, Development of a human papillomavirus competitive luminex immunoassay for 9 HPV types. Hum Vaccin Immunother 2014 10 2174-103
34. World Health Organization Acellular pertussis vaccines. Available at http://www.who.int/biologicals/areas/vaccines/apertussis/en/. Accessed July 25, 2014.
35. Miettinen O, Nurminen M., Comparative analysis of two rates. Stat Med 1985 4 213 226
36. Van Damme P, Olsson SE, Block S, Immunogenicity and safety of a 9-valent HPV vaccine. Pediatrics. In press.
37. Olsson SE, Van Damme P, Vesikari T, Immunogenicity and safety of a novel 9-valent HPV vaccine in girls 9-15 years of age compared to the quadrivalent vaccine. 2014 Paper presented at: IPV 2014